A practical reference on melanocortin receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-06 and is reviewed periodically as new material appears.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
=== Pharmacodynamics === The mechanism of action of tiflorex has apparently never been studied. Similar compounds such as fenfluramine, norfenfluramine and 4-MTA act as selective serotonin releasing agents and 5-HT2 receptor agonists. Fenfluramine in particular causes very similar side effects and appetite suppression at therapeutically relevant doses.
Some research has shown that sea ice diatoms can use an ancient bacterial metabolic pathway known as the Entner−Doudoroff pathway (EDP) to maintain metabolism and energy production during light limitation. The ability of diatoms to use light for energy also depends on air temperature. As it gets colder, the thylakoid membranes within the microalgae plastids can become dense and compact, which influences how certain photosynthetic proteins (such as the proteins necessary for Photosystems I & II) function and self-assemble. Sea ice diatoms can alter the saturation of the fatty acids that compose the thylakoid membranes as temperatures decrease, which can provide more fluidity to these membranes and result in proper folding of photosynthetic proteins at subzero temperatures. As temperatures within brine pockets decrease, organisms that survive within brine pockets produce substances that can help prevent freezing. Some sea ice diatoms can produce specialized ice-binding proteins and extracellular polymeric substances, which can help increase the habitat space available within a brine pocket by preventing ice formation and reducing the freezing temperature of the brine. Decreased temperatures can also reduce the efficiency of important physiological processes within many microorganisms. Psychrophilic diatoms and bacteria have the ability to regulate their production of proteins, DNA, and enzymes required for metabolism to help maintain metabolic efficiency in colder temperatures.
=== Supercritical fluid chromatography === Supercritical fluid chromatography (SFC) can be used on an analytical scale, where it combines many of the advantages of high-performance liquid chromatography (HPLC) and gas chromatography (GC). It can be used with non-volatile and thermally labile analytes (unlike GC) and can be used with the universal flame ionization detector (unlike HPLC), as well as producing narrower peaks due to rapid diffusion. In practice, the advantages offered by SFC have not been sufficient to displace the widely used HPLC and GC, except in a few cases such as chiral separations and analysis of high-molecular-weight hydrocarbons. For manufacturing, efficient preparative simulated moving bed units are available. The purity of the final products is very high, but the cost makes it suitable only for very high-value materials such as pharmaceuticals.
adenosyl radical, which converts to deoxyadenosine (AdO): classic rSAM reaction, also cogenerates methionine S-adenosyl homocysteine, releasing methyl radical methylthioadenosine (SMT), homoalanine radical
Sources: en.wikipedia.org
A higher ratio of body surface area (proportional to heat loss) to body volume (proportional to heat production) A higher proportional surface area of the head A low amount of musculature and the inability to shiver A lack of thermal insulation, e.g., subcutaneous fat and fine body hair (especially in prematurely born children) An inability to move away from cold areas, air currents or heat-draining materials An inability to use additional ways of keeping warm (e.g., drying their skin, putting on clothing, moving into warmer areas, or performing physical exercise) A nervous system that is not fully developed and does not respond quickly and/or properly to cold (e.g., by contracting blood vessels in and just below the skin: vasoconstriction). Heat production in brown fat provides an infant with an alternative means of heat regulation.
Coal and oil are possible examples of constituents which may have undergone changes over geologic time periods. Chalk and limestone are examples of secretions (marine animal shells) which are of geologic age. Grass and wood are biogenic constituents of contemporary origin. Pearls, silk and ambergris are examples of secretions of contemporary origin. Biogenic neurotransmitters.
Other factors that have potentially influenced the increase in drug delivery system development may include the increasing prevalence of both chronic and infectious diseases, as well as a general increased understanding of the pharmacology, pharmacokinetics, and pharmacodynamics of many drugs.
Theranos had reportedly been on the verge of bankruptcy, with the loan meant to keep the company solvent into 2018. The loan was secured by Theranos's patents. On April 10, 2018, the company laid off the majority of workers in a renewed bid to avoid bankruptcy. The company's total headcount was now fewer than 25 employees, after having 800 employees at its peak. Softbank's Fortress bought up Theranos patents and later, taking advantage of the new market conditions in the midst of the COVID-19 pandemic, set up a shell company called Labrador Diagnostics, which sued one of the companies making COVID-19 tests, saying that its test violated those Theranos patents. Theranos was still being issued patents into 2019 because of the lengthy patent application process.
== Uses == TCFH itself is a common reagent used in the preparation of uronium and guanidinium salts used for amide bond formation and peptide synthesis, such as HATU. Amide bond formation with TCFH can be performed in a wide range of organic solvents, most commonly acetonitrile, but also water and in the solid state. Reactions typically require an added Brønsted base, and a wide range can be employed including N,N-diisopropylethylamine (DIPEA). In reactions of carboxylic acids with TCFH and a weakly Lewis basic amine like DIPEA, formation of an acid chloride or anhydride as the active acylating agent occurs. Use of N-methylimidazole (NMI) as a base, with both Brønsted and Lewis basic properties, provides some unique advantages. Reactions of carboxylic acids with TCFH and a strongly Lewis basic amine like NMI lead to in situ formation of an N-acyl imidazolium ion (NAI) as the active acylating agent.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
The lyophilised solid is best kept cold, dry and dark, typically at minus twenty degrees Celsius. Moisture and repeated warming cycles are the main causes of degradation. Solutions prepared from the powder are less stable and are normally used quickly.